Key result
GMP-grade CD19 CAR T-cell generation proves feasible and functional in active systemic lupus erythematosus.
Why the study?
It is unclear whether sufficient amounts of functional autologous CAR T cells can be generated from patients with autoimmune diseases due to intrinsic T-cell abnormalities and immune suppression.
Is it feasible to generate sufficient amounts of functional autologous anti-CD19 CAR T cells from patients with active systemic lupus erythematosus?
Is it feasible to generate sufficient amounts of functional autologous anti-CD19 CAR T cells from patients with active systemic lupus erythematosus?
Answers are grounded in this paper and cite their sources.
It is feasible to generate clinical-grade, functional anti-CD19 CAR T cells from patients with active systemic lupus erythematosus despite intrinsic T-cell abnormalities and prior immunosuppression.
Although it has been shown that the production of functional chimeric antigen receptor T cells is feasible in patients with B-cell malignancies, it is currently unclear whether sufficient amounts of functional autologous CAR T cells can be generated from patients with autoimmune diseases. Intrinsic T-cell abnormalities and T-cell-targeted immune suppression in patients with autoimmunity may hamper the retrieval of sufficient T cells and their transduction and expansion into CAR T cells. Patients with active systemic lupus erythematosus (SLE) underwent leukapheresis after tapering glucocorticoids and stopping T-cell-suppressive drugs. This material was used as source for manufacturing anti-CD19 CAR T-cell products (CAR) in clinical scale. Cells were transduced with a lentiviral anti-CD19 CAR vector and expanded under good manufacturing practice (GMP) conditions using a closed, semi-automatic system. Functionality of these CAR T cells derived from autoimmune patient cells was tested in vitro. Six SLE patients were analyzed. Leukapheresis could be successfully performed in all patients yielding sufficient T-cell numbers for clinical scale CAR T-cell production. In addition, CAR T cells showed high expansion rates and viability, leading to CAR T cells in sufficient doses and quality for clinical use. CAR T cells from all patients showed specific cytotoxicity against CD19+ cell lines in vitro. GMP grade generation of CD19 CAR T-cell products suitable for clinical use is feasible in patients with autoimmune disease.
No takes yet. Share an insight, caveat, or question.
Kretschmann et al. (2022) studied Active systemic lupus erythematosus (SLE) (n=6). Generation of anti-CD19 CAR T-cell products was evaluated on Feasibility of generating clinical scale CAR T-cell products and in vitro functionality. GMP grade generation of CD19 CAR T-cell products was feasible in all 6 patients with active systemic lupus erythematosus, yielding sufficient doses and specific in vitro cytotoxicity.
Synapse has enriched 10 related papers. Consider them for comparative context: